PharmaJet and Mundipharma partner to expand access to needle-free technology in emerging markets

SINGAPORE — July 25, 2018 — PharmaJet® the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet’s Tropis® and Stratis® needle-free devices across more than 120 markets worldwide. Tropis® (ID) and Stratis® (IM/SC) devices are both optimized for vaccine immunizations.

PharmaJet to present latest Research Results at World Vaccine Congress

GOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Phase 1 clinical trial for Hantavirus vaccines yields positive interim results

GOLDEN, Colo. — March 13, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.

Zika Virus vaccine shows significantly higher immune response with Needle-free delivery

GOLDEN, Colo. — Jan. 9, 2018 — PharmaJet, the maker of innovative, needle-free injection technology announced that a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.